GLP-1 Clinical Trial Data Simplified: What the Numbers Mean for You

Prices verified May 22, 2026 · Updated for 2026

Why trial data matters (and why it's confusing)

Every GLP-1 provider cites clinical trial data to promote their medication. "Patients lost an average of 15%!" or "Up to 22% weight loss!" These numbers are real—but they need context. Clinical trials are conducted under specific conditions, with specific patient populations, over specific timeframes. The numbers don't automatically translate to your experience. This guide explains what the major trials actually measured, what the numbers mean, and how to use them to set realistic expectations.

The landmark trials at a glance

What "average weight loss" actually means

When a trial reports "14.9% average weight loss," that's the mean across all participants who stayed in the study. It's not a guarantee, and it's not a cap. Here's what the distribution typically looks like:

• About 10–15% of patients lose <5% of body weight (considered "non-responders")
• About 30–40% lose 5–15% (moderate responders)
• About 30–35% lose 15–25% (strong responders)
• About 10–15% lose >25% (exceptional responders)

You can't know which category you'll fall into before starting. Genetics, baseline metabolism, adherence to lifestyle changes, and starting BMI all influence response. The most reliable predictor: patients who lose at least 5% by week 12–16 tend to continue losing and reach meaningful totals.

The SELECT trial: why it changed everything

The SELECT trial (2023) was the first to prove that a GLP-1 medication reduces cardiovascular events—not just weight. Over 3.4 years, semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with established heart disease. This earned Wegovy an expanded FDA indication for cardiovascular risk reduction and fundamentally changed how insurers view GLP-1 coverage.

Weight loss in SELECT was lower (~9.4%) than in STEP 1 (~14.9%) because the patient population was older, had more comorbidities, and many were already on other medications. The cardiovascular benefit appeared independent of the amount of weight lost.

Head-to-head: what SURMOUNT-5 settled

Until SURMOUNT-5, comparisons between semaglutide and tirzepatide relied on cross-trial analysis (comparing STEP 1 to SURMOUNT-1). SURMOUNT-5 was the first direct head-to-head trial. Results confirmed what cross-trial data suggested: tirzepatide produces approximately 6 percentage points more weight loss than semaglutide at maximum approved doses. The difference was statistically significant and clinically meaningful.

Pipeline trials to watch

REDEFINE (CagriSema)

CagriSema combines semaglutide with cagrilintide, an amylin receptor agonist. The REDEFINE 1 trial reported 22.7% weight loss—within striking distance of the SURMOUNT-1 tirzepatide results. FDA decision expected 2026. If approved, CagriSema would be a weekly injection option competitive with Zepbound.

Retatrutide Phase 3

Retatrutide (Eli Lilly) is a triple GLP-1/GIP/glucagon agonist. Phase 2 data showed a staggering 24.2% weight loss at 48 weeks—the highest ever recorded in a clinical trial. Phase 3 results are expected 2026–2027. If confirmed, retatrutide would redefine the ceiling for pharmacological weight loss.

How to use this data

Clinical trial numbers are starting points, not contracts. Use them to:

• Set realistic expectations: Plan for 10–20% weight loss over 12–18 months, not overnight transformation.
• Compare medications: All else equal, higher average weight loss means better odds of significant results for you.
• Evaluate provider claims: If a provider promises more weight loss than clinical trials demonstrate, that's a red flag.
• Decide when to switch: If you haven't lost at least 5% by week 16, discuss switching medications with your provider.